China’s growing role in pharmaceutical supply chains raises serious concerns. Recent reports of GLP-1 ingredients produced in bug-infested, mold-covered facilities underlines the risks of relying on a system with inadequate oversight. American patients should not pay the price of U.S. companies being dependent on Chinese drug manufacturing. bloomberg.com/news/articles/…
FDA inspectors found black mold on equipment, significant insect activity in ceilings, and other egregious conditions at two Chinese factories producing active ingredients for compounded GLP-1 drugs. American pharma companies are putting U.S. citizens at risk by depending on China to produce medicine. bloomberg.com/news/articles/…